A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

JP Laubach, JJ Moslehi, SA Francis, JF San Miguel, Pieter Sonneveld, RZ Orlowski, P Moreau, L Rosinol, EA Faber, P Voorhees, MV Mateos, L Marquez, HB Feng, A Desai, HV de Velde, J Elliott, HL Shi, E Dow, N Jobanputra, DL EsseltineL Niculescu, KC Anderson, S Lonial, PG Richardson

Research output: Contribution to journalArticleAcademicpeer-review

45 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)547-560
Number of pages14
JournalBritish Journal of Haematology
Issue number4
Publication statusPublished - 2017

Research programs

  • EMC OR-01

Cite this